sar405838
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 13, 2012 (NCT01636479)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- p53-binding protein Mdm-2ANTAGONIST
MDM2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sar405838
- sar405838
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01985191 | Phase 1 | Nov 1, 2013 | Merck KGaA, Sanofi |
| NCT01636479 | Phase 1 | Jul 13, 2012 | Sanofi |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 2 | 2 | 1 | 2012 |
| Merck KGaA | For profit | 1 | 0 | 1 | 2013 |
2 organizations
Page 1 / 1